The impact of race and ethnicity on diffuse large B-cell lymphoma outcomes within the veterans health administration (VHA)

Andrew Ta, Supreet Kaur, Michael Mader, Kathleen Franklin, Madison Williams, Ryan Williams, Jean Pierre Blaize, Amna Naqvi, Snegha Ananth, Michael Song, Brian Oliver Warnecke, Abhishek Pandya, Lakene Raissa Djoufack Djoumessi, Phillip Nazarewicz, Manuel Espinoza-Gutarra, Kana Tai Lucero, Jennifer Whitehead, Alaq Al-Abayechi, Lauren Boyle, Sophia LeeGabriel Roman Souza, Esteban Toro Velez, Ian Mines, Zohra Nooruddin

Research output: Contribution to journalArticlepeer-review

Abstract

We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 patients who met inclusion criteria were predominantly male (97%) and white (75%). Median age of diagnosis for Black patients was 63 years vs 69 years for the entire cohort (p < 0.001). However, patients in each race/ethnicity subgroup presented with similar rates of stage I/II and III/IV disease, IPI score, cell of origin and HIT status. Outcomes analysis revealed similar treatment, response rates, median overall survival, and 1-, 3-, and 5-year survival across all subgroups. Hispanic patients had a 21% lower risk of death (HR = 0.79) than white patients, and Black patients had no significant difference in survival (HR = 0.98). This large retrospective study shows that when standard of care therapy is given within an equal access system, short-term treatment and survival outcomes are the same for all races.

Original languageEnglish (US)
Pages (from-to)1090-1099
Number of pages10
JournalLeukemia and Lymphoma
Volume65
Issue number8
DOIs
StatePublished - 2024

Keywords

  • African Americans
  • Hispanics
  • Lymphoma and Hodgkin disease
  • diffuse large B-cell lymphoma
  • disparities
  • health disparities

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The impact of race and ethnicity on diffuse large B-cell lymphoma outcomes within the veterans health administration (VHA)'. Together they form a unique fingerprint.

Cite this